Edition:
United States

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

1.64USD
16 Nov 2018
Change (% chg)

$-0.14 (-7.61%)
Prev Close
$1.77
Open
$1.77
Day's High
$1.84
Day's Low
$1.57
Volume
204,098
Avg. Vol
236,483
52-wk High
$15.00
52-wk Low
$1.57

Chart for

About

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $89.01
Shares Outstanding(Mil.): 46.12
Dividend: --
Yield (%): --

Financials

  AKAO.OQ Industry Sector
P/E (TTM): -- 79.36 29.34
EPS (TTM): -3.96 -- --
ROI: -129.74 -0.30 13.58
ROE: -196.97 -2.98 15.11

FDA knocks back Achaogen's drug for bloodstream infection

The U.S. Food and Drug Administration cleared Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, but shares slumped 25 percent as the drug failed to win approval for treating bloodstream infections.

Jun 26 2018

Achaogen's antibiotic gets FDA nod for urinary tract infections

June 26 The U.S. Food and Drug Administration approved Achaogen Inc's antibiotic to treat adults with complicated urinary tract infections, the company said on Tuesday.

Jun 26 2018

Earnings vs. Estimates